ArticleSurgical endoscopy2026
Cost‑effectiveness analysis of indocyanine green fluorescence imaging-guided laparoscopic lymphadenectomy for gastric cancer in China.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundIndocyanine green (ICG) fluorescence imaging-guided laparoscopic lymphadenectomy has been proven to be safe and effective, not only in improving the number of lymph nodes (LNs) but also in prolonging survival in patients with gastric cancer (GC) compared with conventional laparoscopic lymphadenectomy. However, a cost‑effectiveness analysis of this technology has been lacking. This study aims to evaluate the cost-effectiveness of ICG fluorescence imaging-guided laparoscopic lymphadenectomy in GC patients.
methodsBased on FUGES-012 trial, we developed a two-step decision analytic model, including a decision tree model and a partitioned survival model (PSM) with a cycle of 1 month and a 20-year time horizon, to evaluate the cost-effectiveness of ICG fluorescence imaging-guided laparoscopic lymphadenectomy from the perspective of China healthcare system. The primary outcomes included costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). The economic feasibility of the intervention was determined by comparing the ICER against a willingness-to-pay (WTP) threshold set at 3 times China's 2024 per capita GDP. To assess the robustness of the model results, we conducted one-way deterministic sensitivity analysis (DSA) and probabilistic sensitivity analysis (PSA). A survival benefit threshold analysis was performed to address the uncertainty in the survival benefit.
resultsIn the base-case analysis, ICG fluorescence imaging-guided laparoscopic lymphadenectomy yielded an ICER of $ 886.30 per additional QALY gained, below the WTP threshold. The DSA reveals that the ICER is most sensitive to discount, cost of progressive disease (PD), additional cost of fluorescence imaging, and utility of progression-free survival (PFS). The PSA demonstrates that ICG fluorescence imaging-guided laparoscopic lymphadenectomy has a probability of 99.30% being cost-effective at WTP. The threshold analysis demonstrated that the cost-effectiveness conclusion is robust to uncertainty in the survival benefit estimate.
conclusionsCompared to conventional laparoscopic lymphadenectomy, ICG fluorescence imaging-guided laparoscopic lymphadenectomy for GC appears to be a cost-effective option in China.
Indexed as
Identifiers
41269317What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.